NSC-620621(NSC-620621) - 在研适应症：脑干胶质瘤_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Antineoplaston AS2-1、Astugenal

靶点-

作用方式-

作用机制-

治疗领域

肿瘤神经系统疾病

在研适应症

脑干胶质瘤

非在研适应症

食管腺癌前列腺腺癌肾上腺皮质癌+ [45]

原研机构

Burzynski Research Institute, Inc.

在研机构

Burzynski Research Institute, Inc.

非在研机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

63

项与 NSC-620621 相关的临床试验

NCT02864888

/ Not yet recruiting临床3期IIT

A Controlled, Study of the Effect of Combination Antineoplaston Therapy [Atengenal (A10) and Astugenal (AS2-1)] on the QT/QTc Interval In Subjects With Newly Diagnosed Diffuse, Intrinsic, Brainstem Glioma

The primary objective of this protocol study is to investigate the effect of Antineoplaston therapy on the QT/QTc interval in study subjects age 3 to 21 years with newly-diagnosed, diffuse, intrinsic brainstem glioma. This investigation is to be conducted in parallel with a phase 3 efficacy and safety study of combination Antineoplaston therapy + radiation vs. radiation alone (BRI-BT-52).

开始日期2027-06-01

申办/合作机构

Burzynski Research Institute, Inc.

NCT02887040

/ Not yet recruiting临床3期IIT

A Randomized Phase 3 Study of Combination Antineoplaston Therapy [Antineoplastons A10 (Atengenal) and AS2-1 (Astugenal)] Plus Radiation Therapy vs. Radiation Therapy Only in Subjects With Newly Diagnosed Diffuse, Intrinsic, Brainstem Glioma

Patients ≥ 3 years of age with newly-diagnosed, diffuse, intrinsic pontine glioma will be enrolled in this study. However, the primary objectives of this study are to 1) compare overall survival, the time from randomization to death from any cause, for study subjects 3-21 years of age with newly-diagnosed, diffuse, intrinsic pontine glioma who receive Antineoplaston therapy (Atengenal + Astugenal) + radiation therapy vs. radiation therapy alone and 2) describe the toxicity profile (all subjects) for Antineoplaston therapy + radiation therapy vs. radiation therapy alone.
A secondary objective is to compare progression-free survival for study subjects 3-21 years of age with newly-diagnosed, diffuse, intrinsic pontine glioma treated with Antineoplaston therapy + radiation therapy vs. radiation therapy alone.

开始日期2025-06-01

申办/合作机构

Burzynski Research Institute, Inc.

NCT04542681

/ Withdrawn临床1期IIT

A Phase I, Single-Blind, Placebo-Controlled Study Evaluating the Cardiovascular Properties of MANP in African Americans With Hypertension

Evaluate the cardiovascular properties of MANP in AA with Hypertension

开始日期2018-05-01

申办/合作机构

Mayo Clinic

100 项与 NSC-620621 相关的临床结果

登录后查看更多信息

100 项与 NSC-620621 相关的转化医学

登录后查看更多信息

100 项与 NSC-620621 相关的专利（医药）

登录后查看更多信息

17

项与 NSC-620621 相关的文献（医药）

2014-01-01·Oncology Reports3区 · 医学

Demethylation effect of the antineoplaston AS2-1 on genes in colon cancer cells

3区 · 医学

Article

作者: Yutaka Ogata ; Keiko Matono ; Yoshito Akagi ; Kazuo Shirouzu ; Masataka Ushijima ; Hideaki Tsuda

Antineoplastons are naturally occurring peptides and amino acid derivatives found in human blood and urine. antineoplastons have been shown to control neoplastic growth. In the present study, we investigated demethylation effect of the antineoplaston AS2-1 (a mixture of phenylacetylglutamine and phenylacetate in the ratio of 1:4) on various genes in colon cancer cells. An HpaII-MspI methylation microarray was used to investigate the methylation status of 51 genes at the promoter region in HCT116 and KM12SM human colon cancer cells before and after treatment of AS2-1. The expression of protein and mRNA of the demethylated genes by AS2-1 in HCT116 cells was evaluated. In 19 of the 34 methylated genes in HCT116 and in 7 of the 8 methylated genes in KM12SM, the methylation status was downregulated after treatment with 2 mg/ml of AS2-1 for 24 h. AS2-1 dramatically downregulated the methylation status of p15 and ESR1 in HCT116 cells and of MTHFR and MUC2 in KM12SM cells. Both mRNA and protein expression of p15 increased in a dose- and time-dependent manner after treatment with AS2-1. The antineoplaston AS2-1 may normalize the hypermethylation status at the promoter region in various genes including tumor suppressor genes, resulting in activation of the transcription and translation in colon cancer.

2005-01-01·Biomeditsinskaia khimiia

[The regulatory action of dipeptide "Deglutam" on the glutamine metabolized enzymes in the carcinosarcoma SM-1 cells].

Article

The influence of modified antineoplaston AS2-1 (with altered ratio of L-phenylalanine and L-glutamine derivatives, "Deglutam") on the activity of glutamine synthetase, glutaminase isoforms in the carcinosarcoma SM-1, tumor weight, per cent of the inhibition of tumor growth and blood impact index was investigated in rats with carcinosarcoma SM-1. The preparation was administered in the dose of 125 mg/kg twice a day for 12 days (on the 7th day after tumor transplantation). Intensive growth of carcinosarcoma SM-1 was accompanied by activtion of the glutamine metabolizing enzymes. The dose-response effect of "Deglutam" on the studied enzymes depended on the mode of preparation administration. The intragastric administration of the preparation caused the same effect on the glutamine metabolizing of SM-1 cells; as it was earlier observed in rat liver. Administration of the modified preparation ANP AS2-1 (containing L-glutamine derivatives) influences regulation of glutamine metabolism in carcinosarcoma SM-1 cells, possibly, due to formation of substrates in the tissues of the tumor-bearing body similar to glutamine. It is also possible that in the tumor tissues these enzymes have different affinity to glutamine. This may explain greater effectiveness of the synthetic preparation on the basis of L-glutamine derivatives rather than the amino acid itself.

2003-06-01·Surgery Today4区 · 医学

Long-Term Survival Following Treatment with Antineoplastons for Colon Cancer with Unresectable Multiple Liver Metastases: Report of a Case

4区 · 医学

Article

作者: Hideaki Tsuda ; Yoshito Akagi ; Keiko Matono ; Yasumi Araki ; Tsutomu Kumabe ; Hiroshi Hara ; Michio Sata ; Kazuo Shirouzu ; Hideki Saitsu ; Yutaka Ogata

We report a case of survival for nearly 8 years after treatment of unresectable multiple liver metastases from colon cancer, using microwave ablation and the nontoxic antitumor agent, the antineoplastons. A 72-year-old man diagnosed with adenocarcinoma of the ascending colon and 14 bilateral liver metastases underwent a right hemicolectomy combined with microwave ablation of six metastatic liver tumors. We also decided to give antineoplastons to inhibit metastatic tumor growth and recurrence. Antineoplaston A10 was given intravenously, followed by oral antineoplaston AS2-1. Computed tomography scans done 1 and 4 years after the initial diagnosis showed recurrent tumors in S(4) and S(7), respectively. The patient underwent a second and a third microwave ablation of the recurrent tumors, and has survived for nearly 8 years without suffering any serious adverse effects. He is currently free from cancer. This case report demonstrates the potential effectiveness of the nontoxic antitumor agent, the antineoplastons, for controlling liver metastases from colon cancer.

100 项与 NSC-620621 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脑干胶质瘤	临床3期	-	Burzynski Research Institute, Inc.	2025-06-01
卵巢上皮癌	临床2期	美国	Burzynski Research Institute, Inc.	1996-03-05
低级别星形细胞瘤	临床2期	美国	Burzynski Research Institute, Inc.	1996-03-01
前列腺腺癌	临床2期	美国	Burzynski Research Institute, Inc.	1996-02-27
转移性前列腺癌	临床2期	美国	Burzynski Research Institute, Inc.	1996-02-27
中枢神经系统横纹肌瘤	临床2期	美国	Burzynski Research Institute, Inc.	1996-02-01
高级别胶质瘤	临床2期	美国	Burzynski Research Institute, Inc.	1994-04-01
复发性恶性胶质瘤	临床2期	美国	Burzynski Research Institute, Inc.	1994-04-01
室管膜瘤	临床2期	美国	Burzynski Research Institute, Inc.	1966-07-01
胶质瘤	药物发现	美国	Burzynski Research Institute, Inc.	1996-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00003487 (CTgov)	临床2期	食管腺癌	8	Atengenal+Astugenal	遞艱築糧願遞餘窪膚獵(廠鏇積淵壓製鑰齋淵鏇) = 壓淵顧淵襯選餘淵鏇蓋膚蓋構廠願艱廠餘鏇簾 (鬱窪襯遞遞構餘齋獵淵, 憲鹽製夢繭願簾築網醖 ~ 糧夢鑰獵鏇鑰衊窪選蓋) 更多	-	2021-05-14
NCT00003508 (CTgov)	临床2期	恶性间皮瘤	8	Atengenal+Astugenal	(壓糧積觸遞顧淵遞鏇衊) = 願繭願獵蓋選獵齋齋繭築淵範顧鑰獵膚鹽膚糧 (觸糧選鏇衊夢構範構簾, 遞網鹹壓艱願衊範襯淵 ~ 網醖簾遞鏇鹽壓膚糧範) 更多	-	2021-02-21
NCT00003511 (CTgov)	临床2期	多发性骨髓瘤	5	Atengenal+Astugenal	(糧蓋鏇憲鹹構製齋糧網) = 築淵範膚鏇構選襯鏇齋壓選鬱齋蓋鏇憲鹽鑰蓋 (壓顧醖構衊衊範繭夢鏇, 鏇構願顧艱壓鹹鬱鹹觸 ~ 窪繭選窪齋願憲齋膚網) 更多	-	2021-01-28
NCT00003498 (CTgov)	临床2期	非霍奇金淋巴瘤	5	Atengenal+Astugenal	(蓋鏇餘窪構淵築壓糧糧) = 積壓蓋醖憲遞鏇醖觸淵顧淵廠鹹艱糧製膚壓鹽 (簾願廠餘鬱廠窪繭鏇鹹, 願觸壓顧夢鑰醖製壓廠 ~ 艱醖襯願齋憲膚獵醖憲) 更多	-	2020-12-19
NCT00003509 (CTgov)	临床2期	黑色素瘤	13	Atengenal+Astugenal	(製鏇鏇觸膚餘構繭淵衊) = 繭淵鏇窪顧範廠築夢鑰網網艱製鹹鏇鹽壓壓憲 (鏇觸餘餘蓋憲鹹膚蓋蓋, 簾鬱繭襯壓襯壓簾鏇鹽 ~ 蓋窪顧製艱獵築鹽衊膚) 更多	-	2020-12-19
NCT00003526 (CTgov)	临床2期	腺癌 \| 原发部位不明恶性肿瘤	8	Atengenal+Astugenal	(鏇選範壓鬱網選衊積繭) = 窪糧範齋顧蓋淵膚製簾繭觸鏇鬱膚齋簾鑰鑰壓 (衊遞衊窪鑰窪鑰遞範網, 鏇築餘繭襯鏇遞膚襯顧 ~ 淵齋醖廠簾憲鏇鏇膚餘) 更多	-	2020-12-17
NCT00003531 (CTgov)	临床2期	胰腺腺癌	15	Atengenal+Astugenal	(獵鬱構壓觸壓夢餘鑰鑰) = 獵膚夢鑰築鹹鑰願鹹獵獵夢鏇顧顧憲壓衊艱築 (遞積鏇顧衊鏇築糧遞醖, 顧觸襯淵鹹選夢願鹽齋 ~ 餘遞製襯窪遞窪願遞餘) 更多	-	2020-12-17
NCT00003492 (CTgov)	临床2期	未分化大细胞肺癌	9	Atengenal+Astugenal	膚鹹憲鬱網鏇壓淵膚築(積鹽窪襯顧築鹽顧憲願) = 顧夢窪憲願觸選獵淵選艱繭淵淵繭醖憲構繭遞 (淵艱鹽衊願遞壓顧廠齋, 鹹醖窪範壓廠鏇憲廠構 ~ 鹹鹹遞蓋醖範簾淵顧簾) 更多	-	2020-12-16
NCT00003499 (CTgov)	临床2期	低级别 B 细胞非霍奇金淋巴瘤	31	Atengenal+Astugenal	(壓簾壓遞襯觸鏇壓繭獵) = 構築製網範遞艱憲獵衊廠構顧繭顧鬱壓廠襯觸 (膚鑰糧簾積顧觸簾鏇膚, 鹽範蓋顧積鏇簾積鹽遞 ~ 鏇糧齋窪積襯觸餘簾衊) 更多	-	2019-04-16
NCT00003453 (CTgov)	临床2期	肾上腺皮质癌	6	Atengenal+Astugenal	(醖簾網築廠繭築簾齋窪) = 憲鏇膚遞膚構鏇築壓蓋鏇顧鹽鏇鹹構顧憲網夢 (夢製選醖齋鬱鹽鬱壓憲, 簾廠願遞衊窪積鑰膚衊 ~ 選繭築選夢築遞鏇觸夢) 更多	-	2018-05-09